NZ335485A - Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof - Google Patents

Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof

Info

Publication number
NZ335485A
NZ335485A NZ335485A NZ33548597A NZ335485A NZ 335485 A NZ335485 A NZ 335485A NZ 335485 A NZ335485 A NZ 335485A NZ 33548597 A NZ33548597 A NZ 33548597A NZ 335485 A NZ335485 A NZ 335485A
Authority
NZ
New Zealand
Prior art keywords
antigen
nucleic acid
acid molecule
isolated nucleic
cancer associated
Prior art date
Application number
NZ335485A
Other languages
English (en)
Inventor
Yao-Tseng Chen
Matthew Scanlan
Ali Gure
Lloyd J Old
Elke Jager
Alexander Knuth
Jan W Drijfhout
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NZ335485A publication Critical patent/NZ335485A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NZ335485A 1996-10-03 1997-09-15 Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof NZ335485A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/725,182 US5804381A (en) 1996-10-03 1996-10-03 Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
PCT/US1997/016335 WO1998014464A1 (en) 1996-10-03 1997-09-15 Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof

Publications (1)

Publication Number Publication Date
NZ335485A true NZ335485A (en) 2001-01-26

Family

ID=24913488

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335485A NZ335485A (en) 1996-10-03 1997-09-15 Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof

Country Status (14)

Country Link
US (2) US5804381A (enExample)
EP (1) EP0948518B1 (enExample)
JP (1) JP3799483B2 (enExample)
KR (1) KR20000048851A (enExample)
CN (1) CN1283652C (enExample)
AT (1) ATE260930T1 (enExample)
AU (1) AU732068B2 (enExample)
CA (1) CA2266319C (enExample)
DE (1) DE69727966T2 (enExample)
DK (1) DK0948518T3 (enExample)
ES (1) ES2216169T3 (enExample)
NZ (1) NZ335485A (enExample)
PT (1) PT948518E (enExample)
WO (1) WO1998014464A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252052B1 (en) * 1996-10-03 2001-06-26 Cornell Research Foundation, Inc Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US6417165B1 (en) 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US6255470B1 (en) * 1996-10-03 2001-07-03 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule encoding an esophageal cancer associated antigen
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
EP1961820B1 (en) 1997-01-27 2012-11-28 Ludwig Institute for Cancer Research Ltd Vaccine composition comprising LAGE-1 tumor associated nucleic acids or LAGE-1 polypeptides
US6794131B1 (en) 1998-01-27 2004-09-21 Ludwig Institute For Cancer Research Lage-1 tumor associated nucleic acids
US6673350B2 (en) * 1997-05-05 2004-01-06 Ludwig Institute For Cancer Research Tumor associated peptide and uses thereof
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
DE69837273T2 (de) * 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
US7084239B1 (en) 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
EP1806403A3 (en) * 1997-10-08 2008-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
WO2000050595A2 (en) * 1999-02-25 2000-08-31 Ivan Gout Nucleic acid molecules associated with melanoma and thyroid tumors
DE19949595A1 (de) * 1999-10-14 2001-05-03 Deutsches Krebsforsch CTAGE-Genfamilie
ES2306670T3 (es) 1999-10-22 2008-11-16 Sanofi Pasteur Limited Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
US6689742B1 (en) * 2000-02-25 2004-02-10 Chancellors, Masters And Scholars Of The University Of Oxford NY-ESO-1 peptide derivatives, and uses thereof
US20020001805A1 (en) * 2000-03-14 2002-01-03 Roden Richard Bruce Immunogenic ovarian cancer genes
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1752160A3 (en) 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2002086071A2 (en) * 2001-04-20 2002-10-31 Ludwig Institute For Cancer Research Cancer-testis antigens
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US7803382B2 (en) * 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
MY147019A (en) * 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
CA2496888A1 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
WO2005000870A2 (en) * 2003-05-30 2005-01-06 Ludwig Institute Of Cancer Research Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
JP5283335B2 (ja) * 2003-06-17 2013-09-04 マンカインド コーポレイション 各種癌の治療を目的とした腫瘍関連抗原の組合せ
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
WO2005114203A2 (en) * 2004-05-20 2005-12-01 The Regents Of The University Of California Dominant b cell epitopes and methods of making and using thereof
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
WO2006009920A2 (en) 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
PL1833506T3 (pl) 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
KR101294290B1 (ko) * 2004-12-29 2013-08-07 맨카인드 코포레이션 예방 또는 치료를 위해 제ｉ류 주조직 적합성복합체〔ｍｈｃ〕-제한 에피토프에 대한 면역 반응을 유발,향상 및 지속하는 방법
NZ564360A (en) 2005-06-17 2011-03-31 Mannkind Corp Immunogenic product comprising a nucleic acid capable of expressing a PRAME epitope and a PSMA epitope and a peptide composition
US7511118B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
JP5416968B2 (ja) 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
CA2704583A1 (en) 2007-11-07 2009-05-14 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 receptor(dec-205)
US8815564B2 (en) 2008-03-14 2014-08-26 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
BR112012026227A2 (pt) 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
HRP20230443T1 (hr) 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US8490054B2 (en) 2011-09-23 2013-07-16 The United States Of America As Represented By The Secretary Of The Army Software and related software tracking during software modification
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
WO2016040682A1 (en) 2014-09-10 2016-03-17 Genentech, Inc. Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
MX2017015041A (es) 2015-05-29 2018-02-26 Squibb Bristol Myers Co Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos.
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
JP6983776B2 (ja) 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
CN109071665B (zh) 2016-04-18 2022-11-01 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2021116462A1 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5212085A (en) * 1987-12-09 1993-05-18 The General Hospital Corporation Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
DE69837273T2 (de) 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen

Also Published As

Publication number Publication date
EP0948518B1 (en) 2004-03-03
ES2216169T3 (es) 2004-10-16
WO1998014464A1 (en) 1998-04-09
DK0948518T3 (da) 2004-07-05
JP2001507212A (ja) 2001-06-05
EP0948518A4 (en) 2002-01-02
AU732068B2 (en) 2001-04-12
JP3799483B2 (ja) 2006-07-19
CN1283652C (zh) 2006-11-08
US5804381A (en) 1998-09-08
CA2266319A1 (en) 1998-04-09
US6274145B1 (en) 2001-08-14
ATE260930T1 (de) 2004-03-15
DE69727966T2 (de) 2005-02-10
KR20000048851A (ko) 2000-07-25
HK1020968A1 (en) 2000-05-26
EP0948518A1 (en) 1999-10-13
PT948518E (pt) 2004-06-30
CA2266319C (en) 2005-12-20
CN1232467A (zh) 1999-10-20
AU4349597A (en) 1998-04-24
DE69727966D1 (de) 2004-04-08

Similar Documents

Publication Publication Date Title
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
CA2258502A1 (en) Modified factor viii
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
DE69534778D1 (en) Cathepsin-02-protease
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
GEP20105118B (en) Anti-vegf antibodies
PL336470A1 (en) Mammalian cytokin-like factor 7
WO1998021343A8 (en) Genes encoding telomerase proteins
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
ZA9710288B (en) Novel genes encoding telomerase proteins.
MX9708426A (es) Polipeptido hk2 de variante estable.
EP0911397A4 (en) TUMORANTANT PROTEINS, THEIR GENES, AND TUMORANTANT PEPTIDES
ZA975588B (en) Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
FR2706484B1 (fr) Polypeptide mutant de la protéine kinase C, séquences d'acides nucléiques codant pour ledit polypeptide et leurs utilisations.
CA2361987A1 (en) Goodpasture antigen binding protein
IL139604A0 (en) Novel peptides
AU3711597A (en) A novel galanin receptor
WO1996005300A3 (en) Or-1 on orphan receptor belonging to the nuclear receptor family
CA2199403A1 (en) Novel PKA-Binding Proteins and Uses Thereof
CO5280140A1 (es) Antigeno (c42) asociado a tumores
WO1998024896A3 (en) Muteins of obese protein

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired